Select a Region
North America

Browsing Archive: OncologyOncology | EVERSANA

EVERSANA
Posted on March 8, 20253/8/25

Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system

Posted on November 4, 202411/4/24

Integrated Brand Planning with EVERSANA MANAGEMENT CONSULTING

EVERSANA
Posted on July 4, 20247/4/24

Transforming the Future of Pharma Commercialization Through Medical Affairs

EVERSANA
Posted on October 2, 202310/2/23

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

EVERSANA
Posted on September 25, 20239/25/23

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

EVERSANA
Posted on September 25, 20239/25/23

Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?

EVERSANA
Posted on September 25, 20239/25/23

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

EVERSANA
Posted on September 20, 20239/20/23

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant

EVERSANA
Posted on May 1, 20235/1/23

Optimizing Launch & Maximizing Revenue Potential in Europe

EVERSANA
Posted on February 1, 20232/1/23

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

Oncology